The FDA determined this week that Cordis’ recent recall of several versions of its Super Torque angiographic catheters meet the criteria of a Class I recall, a label reserved for those the ...

Cordis, a unit of Johnson & Johnson, announced the launch of its SABER PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease. The SABER Catheter is cleared for use ...

The FDA has identified Cordis’ recall of its angiographic catheter with radiopaque marker bands as Class I, the most serious type of recall. According to a press release from the FDA ...

SAN FRANCISCO--(BUSINESS WIRE)--Cordis Corporation today announced EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary ...

CHICAGO -- Johnson & Johnson's Cordis subsidiary has issued a world-wide recall for about 132,000 balloon catheters used to expand blood vessels after it was determined problems with the devices ...

FREMONT, Calif.--(BUSINESS WIRE)-- Cordis Corporation today announced it has received clearance from the Food and Drug Administration of its latest innovation in guiding catheters: the ADROIT TM 6F ...

Cordis Corp., Johnson & Johnson's stenting arm, notched another 510(k) clearance for its Adroit 6F Guiding Catheter, which the company says can handle more sophisticated lesions. Cordis Corp., the ...

The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon ...

Nonetheless, Cordis continued to develop a wide range of other highly successful devices, like catheters for diagnosing and treating heart disease. The company set up its main manufacturing ...

FREMONT, Calif., Cordis Corporation announced today the launch of the new ELITECROSS™ Support Catheter in the United States and OUTBACK ® Elite Re-Entry Catheter in the United States, Europe and Japan ...